Therapy News and Research

RSS

Novel angiogenic drugs could revolutionize treatment of peripheral arterial disease

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market entry of novel angiogenic agents, including a future blockbuster drug from Genzyme, could revolutionize symptomatic treatment of peripheral arterial disease (PAD).

12 Sep 2007

Ultraconserved non-coding RNAs may be important in human cancer

Research here shows that an obscure form of RNA, part of the protein-making machinery in all cells, might play an important role in human cancer.

12 Sep 2007

Glycemic control medication appears to have favorable effect regarding risk of cardiovascular events

A meta-analysis of previous research suggests that use of pioglitazone, a glycemic control medication for patients with type 2 diabetes, significantly reduces the risk of heart attack, stroke and death, but increases the risk for serious heart failure, according to an article in the September 12 issue of JAMA: The Journal of the American Medical Association.

12 Sep 2007

Diabetes drug Pioglitazone reduces risk of death, heart attack and stroke, but increases risk of heart failure

A drug widely used to treat type 2 diabetes has been found to reduce the risk of death, heart attack (myocardial infarction) or stroke when used alone or in combination with other therapies for diabetes, according to a Cleveland Clinic study.

12 Sep 2007

Link between nicotine and atherosclerosis

It's well known that smoking cigarettes increases risk for a host of serious health problems from cancer to heart disease. Now a new study from Weill Cornell Medical College in New York City looks at how they do their dirty work by contributing to atherosclerosis, or hardening of the arteries. The evidence points to nicotine, the addictive chemical in cigarettes.

11 Sep 2007

Preventing enlarged heart reduces heart failure

For high-blood-pressure patients, preventing or reducing enlarged heart (left ventricular hypertrophy or LVH) reduces risk of heart failure. The study is published in the Sept. 4 Annals of Internal Medicine and led by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City.

11 Sep 2007

Some GPs over-estimate adverse risks associated with the use of beta blocker drugs for heart disease

Some General Practitioners (GPs) over-estimate adverse risks associated with the use of beta blocker drugs in the fight against heart disease, according to research launched today at the British Pharmaceutical Conference (BPC) in Manchester.

11 Sep 2007

$One in two women at high risk of bone fractures don't receive preventative treatment$

One in two women at high risk of bone fractures don't receive preventative treatment

One in two women at high risk of bone fractures don't receive preventative treatment, according to new research presented at the British Pharmaceutical Conference (BPC) in Manchester.

11 Sep 2007

New discovery for Fragile X Syndrome

An important finding has been made by McMaster researchers about Fragile X Syndrome (FXS), a sex-linked genetic disorder that affects approximately one in 4,000 males and one in 6,000 females.

11 Sep 2007

St. Jude follows outcomes of stem cell transplant survivors

Patient care at St. Jude doesn't stop when the child is cured. The end of successful therapy is the start of many years of follow-up care. This care is aimed at helping make the recovery process successful and preparing the family and hometown doctor for long-term complications that might arise from the disease or its treatment.

11 Sep 2007

Smoke-free environments help smokers quit

With Pennsylvania's elected leaders debating the need for a smoking ban, yet another reason is emerging for the Keystone State to clear the air.

11 Sep 2007

Most chronic sinusitis cases are from fungal-induced inflamma

Accentia Biopharmaceuticals announces evidence that most, if not all cases of chronic sinusitis (CS), are due to a fungal-induced inflammation as originally proposed by investigators at the Mayo Clinic.

11 Sep 2007

Incidents of serious adverse drug events more than double

Incidents of serious adverse drug events including deaths reported to the U.S. Food and Drug Administration (FDA) rose by more than double over a seven year period and painkillers and immune-system boosters were responsible for most.

11 Sep 2007

New approaches to transcutaneous electrical nerve stimulation studied

Current post-operative pain control methods have proved inadequate for those who have undergone total knee replacement (TKR), according to University of Iowa College of Nursing researcher.

11 Sep 2007

Most comprehensive recommendations related to lung cancer

New evidenced-based guidelines from the American College of Chest Physicians (ACCP) recommend against the use of low-dose computed tomography (LDCT) for the general screening of lung cancer.

11 Sep 2007

John Cheatham receives prestigious award for work on congenital heart disease

The Pediatric Interventional Cardiac Symposium (PICS) & Adult Interventional Cardiac Symposium (AICS) Lifetime Achievement Award for 2007 was recently presented to John P. Cheatham, MD, Co-Director of The Heart Center at Columbus Children's Hospital and Professor of Pediatrics & Internal Medicine at The Ohio State University College of Medicine.

11 Sep 2007

A neurostimulator device that detects, stops seizures under study at Medical College of Georgia

A small device implanted in the skull that detects oncoming seizures, then delivers a brief electrical stimulus to the brain to stop them is under study at the Medical College of Georgia.

11 Sep 2007

GP prescribing of antibiotics in question

GPs prescribing antibiotics often rely on their personal preferences and experience, rather than clinical evidence, says new research launched at the British Pharmaceutical Conference (BPC) in Manchester.

11 Sep 2007

Adverse drug events on the rise

The number of serious adverse drug events reported to the U.S. Food and Drug Administration (FDA) more than doubled between 1998 and 2005, as did deaths associated with adverse drug events, according to a report in the September 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

11 Sep 2007

Merck/Gilead once-a-day AIDS pill not available in most places

AIDS Healthcare Foundation (AHF) today called on Gilead Sciences and Merck to immediately register and distribute the three-in-one, once daily lifesaving HIV treatment, Atripla, in developing countries.

10 Sep 2007